Trending NewsTrending NewsNYSE:RCUS Arcus Biosciences (RCUS) Stock Price, News & Analysis $19.47 +0.37 (+1.94%) Closing price 03:59 PM EasternExtended Trading$19.25 -0.22 (-1.14%) As of 06:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Arcus Biosciences Stock (NYSE:RCUS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Arcus Biosciences alerts:Sign Up Key Stats Today's Range$17.43▼$19.6250-Day Range$19.01▼$31.4252-Week Range$16.41▼$31.74Volume8.37 million shsAverage Volume1.38 million shsMarket Capitalization$2.48 billionP/E RatioN/ADividend YieldN/APrice Target$39.64Consensus RatingModerate Buy Company Overview Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for cancer and other serious diseases. The company uses its research platform to discover and advance medicines designed to target immune suppression and other biological mechanisms involved in tumor growth. Arcus’s oncology pipeline has included antibody-based and small-molecule therapies aimed at targets such as TIGIT, PD-1, CD73, and the adenosine A2A and A2B receptors. Its key development programs have included domvanalimab, zimberelimab, quemliclustat, and etrumadenant, which have been evaluated in clinical studies across several cancer types, including lung, gastrointestinal, and colorectal cancers. Founded in 2015 and headquartered in Hayward, California, Arcus conducts research and clinical-development activities intended to support potential commercialization in international markets. The company has maintained a strategic collaboration with Gilead Sciences, which has supported the development and potential commercialization of several Arcus programs. Arcus was co-founded by Terry Rosen and Juan Jaén; Rosen has served as chief executive officer, while Jaén has held senior leadership roles focused on research and development.AI Generated. May Contain Errors. Read More Arcus Biosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks70th Percentile Overall ScoreRCUS MarketRank™: 3.500662251655 of 5 starsArcus Biosciences scored higher than 70% of companies evaluated by MarketBeat, and ranked 222nd out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingArcus Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.69, and is based on no strong buy ratings, 12 buy ratings, 3 hold ratings, and 1 sell rating.Upside PotentialArcus Biosciences has a consensus price target of $39.64, representing about 106.0% upside from its current price of $19.24.Amount of Analyst CoverageArcus Biosciences has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Arcus Biosciences' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Arcus Biosciences are expected to grow in the coming year, from ($3.55) to ($3.12) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Arcus Biosciences is -4.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Arcus Biosciences is -4.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioArcus Biosciences has a P/B Ratio of 3.30. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Arcus Biosciences' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted11.14% of the float of Arcus Biosciences has been sold short.Short Interest Ratio / Days to CoverArcus Biosciences has a short interest ratio ("days to cover") of 7.64.Change versus previous monthShort interest in Arcus Biosciences has recently decreased by 5.08%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldArcus Biosciences does not currently pay a dividend.Dividend GrowthArcus Biosciences does not have a long track record of dividend growth. News and Social Media2.0 / 5News Sentiment0.23 News SentimentArcus Biosciences has a news sentiment score of 0.23. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.47 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 26 news articles for Arcus Biosciences this week, compared to 5 articles on an average week.Search InterestOnly 4 people have searched for RCUS on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Arcus Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $84,810.00 in company stock.Percentage Held by Insiders7.60% of the stock of Arcus Biosciences is held by insiders.Percentage Held by Institutions92.89% of the stock of Arcus Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Arcus Biosciences' insider trading history. Receive RCUS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Arcus Biosciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. RCUS Stock News HeadlinesArcus Biosciences Prices $250 Mln Public Offering At $17.50/ShareOctober 22 at 11:28 AM | rttnews.comArcus Shares Fall After Offering PricedOctober 22 at 11:28 AM | marketwatch.comYour book is insideBlane Markham and the Markham Trading Team are giving readers a limited window to download their options strategy guide, titled How To Turn 100 Into 1000 Gains, before it moves behind a paywall. The guide walks through options trading concepts the team uses in its own research and education materials. Once the paywall goes up, free access ends for good.October 22 at 1:00 AM | TradeWins (Ad)Arcus Biosciences, Inc. estimates $694.0 million in cash, cash equivalents and marketable securities as of September 30, 2026October 22 at 11:28 AM | msn.comArcus Biosciences Prices $250 Million Common Stock Offering; Shares Down Pre-BellOctober 22 at 11:28 AM | finance.yahoo.comArcus Biosciences slides 20% on stock offering, kidney-cancer dataOctober 22 at 11:28 AM | seekingalpha.comArcus Biosciences prices $250M public offering at $17.50 per shareOctober 22 at 11:28 AM | msn.comArcus Biosciences Announces Pricing of $250 Million Public Offering of Common StockOctober 21 at 10:53 PM | businesswire.comSee More Headlines RCUS Stock Analysis - Frequently Asked Questions How have RCUS shares performed this year? Arcus Biosciences' stock was trading at $23.90 at the beginning of the year. Since then, RCUS stock has decreased by 19.5% and is now trading at $19.2430. How were Arcus Biosciences' earnings last quarter? Arcus Biosciences, Inc. (NYSE:RCUS) announced its quarterly earnings results on Wednesday, August, 5th. The company reported ($0.72) EPS for the quarter, topping the consensus estimate of ($0.89) by $0.17. Arcus Biosciences's revenue was down 74.4% on a year-over-year basis. Read the conference call transcript. When did Arcus Biosciences IPO? Arcus Biosciences (RCUS) raised $112 million in an initial public offering (IPO) on Thursday, March 15th 2018. The company issued 8,000,000 shares at a price of $13.00-$15.00 per share. Citigroup, Goldman Sachs and Leerink Partners served as the underwriters for the IPO. Who are Arcus Biosciences' major shareholders? Arcus Biosciences' top institutional investors include State of Alaska Department of Revenue (0.01%) and GAMMA Investing LLC. Insiders that own company stock include Gilead Sciences, Inc, Terry J Rosen, Juan C Jaen, Jennifer Jarrett, Carolyn C Tang, Robert C Goeltz II, Richard Markus, Alexander Azoy and Yasunori Kaneko. View institutional ownership trends. How do I buy shares of Arcus Biosciences? Shares of RCUS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Arcus Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Arcus Biosciences investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Alibaba Group (BABA), Pfizer (PFE), Viking Therapeutics (VKTX) and Micron Technology (MU). Company Calendar Last Earnings8/05/2026Today10/22/2026Next Earnings (Estimated)10/27/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1d) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 RCUS's financial health is in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNYSE SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNYSE:RCUS CIK1724521 Webwww.arcusbio.com Phone(510) 694-6200FaxN/AEmployees601Year Founded2015Price Target and Rating Average Price Target for Arcus Biosciences$39.64 High Price Target$50.00 Low Price Target$23.00 Potential Upside/Downside+103.6%Consensus RatingModerate Buy Rating Score (0-4)2.69 Research Coverage16 Analysts Profitability EPS (Trailing Twelve Months)($3.90) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$353 million Net Margins-393.16% Pretax Margin-393.16% Return on Equity-89.54% Return on Assets-45.61% Debt Debt-to-Equity Ratio0.22 Current Ratio3.82 Quick Ratio3.82 Sales & Book Value Annual Sales$247 million Price / Sales10.04 Cash FlowN/A Price / Cash FlowN/A Book Value$5.84 per share Price / Book3.33Miscellaneous Outstanding Shares127,330,000Free Float117,656,000Market Cap$2.48 billion OptionableOptionable Beta0.94 Social Links 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (NYSE:RCUS) was last updated on 10/22/2026 by MarketBeat.com Staff. From Our PartnersFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leadin...Weiss Ratings | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredLast call for your free 0DTE reportThe 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, p...Profits Run | SponsoredYour book is insideBlane Markham and the Markham Trading Team are giving readers a limited window to download their options strat...TradeWins | SponsoredWhy Some AI Stocks Already Surged Over 300 PercentJason Bodner's system flagged Nvidia before a 7000 percent run, Super Micro Computer before a 2600 percent run...Brownstone Research | SponsoredSpaceX is worth trillions. This one's $14.It is not SpaceX, Tesla, Starlink, or Neuralink. But Elon's rocket company shows up in this stock's paperwork,...Behind the Markets | SponsoredIf you keep cash in a U.S. bank account… read this NOWSince 2020, U.S. banks have been required to keep zero percent of deposits on hand, lending out nearly every d...Banyan Hill Publishing | SponsoredThis free guide explains options the way they should be taughtMost options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before th...Base Camp Trading | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arcus Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arcus Biosciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
